Assessment of a HER2 scoring system for gastric cancer: results from a validation study
By M. Hofmann, O. Stoss, D. Shi, R. Büttner, M. V. Vijver, Woosuk Kim, A. Ochiai, J. Rüschoff, T. Henkel. Histopathology, 2008
1,204 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/e76d2809976e93bb993f89ab85d31905370b3048
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- A. Bertotti
- A. Bardelli
- P. Comoglio
- Livio Trusolino
- Giorgia Migliardi
- F. Di Nicolantonio
- S. Siena
- A. Sartore-Bianchi
Citations in the corpus
- Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. (2009, neutral): “3, 11), and 20% to 24% of gastric cancers (5, 12).”
- A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. (2011, methodology): “HercepTest-based HER2 scoring followed the consensus panel recommendations for gastric cancer (51).”
- Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer (2014, background): “For HER2, an IHC score of 2+ or more was defined as positive, and IHC scores of 0 and 1+ were defined as negative [40].”
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets (2012, methodology): “experienced pathologist (LKH) according to the scoring system of [4].”
- Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications (2014, neutral): “Table 1 shows consensus panel recommendations on HER2 scoring for gastric/esophageal cancer [60, 61].”